SEARCH

SEARCH BY CITATION

References

  • 1
    De Vere White RW, Stapp E. Predicting prognosis in patients with superficial bladder cancer. Oncology 1998; 12: 171723.
  • 2
    Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J. Urol. 1997; 15: 848.
  • 3
    Okajima E, Hirao K. Anti-cancer drug intravesical treatment to superficial bladder tumor. In: Yoshida O (ed.). Developing with New Bladder Tumor Treatment. Kanehara, Tokyo, 1993; 105111(in Japanese).
  • 4
    Takashi M, Murase T, Mitsuya H et al. Statistical analysis of recurrence factors in superficial bladder cancer: Estimation with Cox's proportional hazards model. Jpn. J. Urol. 1987; 78: 3949 (in Japanese).
  • 5
    Kobashi K. Statistical analysis of recurrent factors in superficial bladder cancer: Natural history of superficial bladder cancer. Jpn. J. Urol. 1993; 84: 118896 (in Japanese).
  • 6
    Allard P, Bernard P, Frader Y, Tetu B. The early clinical course of primary Ta and T1 bladder cancer: A proposed prognostic index. Br. J. Urol. 1998; 81: 6928.
  • 7
    Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur. Urol. 2002; 41: 52331.
  • 8
    Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol. 2000; 163: 738.
  • 9
    Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y. Chromosome 9 deletions and recurrence of superficial bladder cancer: Identification of four regions of prognostic interest. Oncogene 2000; 19: 631723.
  • 10
    Krause FS, Feil G, Bichler KH. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer. Anticancer Res. 2000; 20: 50238.
  • 11
    Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW, Pauwels RP. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 2000; 88: 2598605.
  • 12
    Simon R, Eltze E, Schafer KL et al. Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells. Cancer Res. 2001; 61: 35562.
  • 13
    Van Tilborg AA, De Vries A, De Bont M, Groenfeld LE, Van Der Kwast TH, Zwarthoff EC. Molecular evolution of multiple recurrent cancers of the bladder. Hum. Mol. Genet. 2000; 9: 297380.
  • 14
    Dalbagni G, Ren ZP, Herr H, Cordon-Cardo C, Reuter V. Genetic alterations in TP53 in recurrent urothelial cancer. A longitudinal study. Clin. Cancer Res. 2001; 7: 2797801.
  • 15
    Hartmann A, Rosner U, Schlake G et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Invest. 2000; 80: 70918.
  • 16
    Dong JT, Lamb PW, Rinker-Schaeffer CW et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995; 268: 8846.
  • 17
    Dong JT, Suzuki H, Pin SS et al. Down-regulation of the KAI1 metastasis suppressor gene during the progression of human prostatic cancer infrequently involves gene mutation or allelic loss. Cancer Res. 1996; 56: 438790.
  • 18
    Friess H, Guo XZ, Tempia-Caliera AA et al. Differential expression of metastasis-associated genes in papilla of Vater and pancreatic cancer correlates with disease stage. J. Clin. Oncol. 2001; 19: 242232.
  • 19
    Ow K, Delprado W, Fisher R et al. Relationship between expression of the KAI1 metastasis suppressor and other markers of advanced bladder cancer. J. Pathol. 2000; 191: 3947.
  • 20
    Huang CI, Kohno N, Ogawa E, Adachi M, Taki T, Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am. J. Pathol. 1998; 153: 97383.
  • 21
    Yang X, Wei LL, Tang C, Slack R, Mueller S, Lippman ME. Overexpression of KAI1 suppresses in vitro invasiveness and in vivo metastasis in breast cancer cells. Cancer Res. 2001; 61: 52848.
  • 22
    Takaoka A, Hinoda Y, Satoh S et al. Suppression of invasive properties of colon cancer cells by a metastasis suppressor KAI1 gene. Oncogene 1998; 16: 144353.
  • 23
    Takaoka A, Hinoda Y, Sato S et al. Reduced invasive and metastatic potentials of kai1-transfected melanoma cells. Jpn. J. Cancer Res. 1998; 89: 397404.
  • 24
    Jackson P, Kingsley EA, Russell PJ. Inverse correlation between KAI1 mRNA levels and invasive behaviour in bladder cancer cell lines. Cancer Lett. 2000; 156: 917.
  • 25
    Uchida S, Shimada Y, Watanabe G et al. Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 1999; 79: 116873.
  • 26
    Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, Barrett JC. Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res. 1999; 59: 572431.
  • 27
    Liu FS, Chen JT, Dong JT et al. KAI1 metastasis suppressor gene is frequently down-regulated in cervical carcinoma. Am. J. Pathol. 2001; 159: 162934.
  • 28
    Liu FS, Dong JT, Chen JT, Hsieh YT, Ho ES, Hung MJ. Frequent down-regulation and lack of mutation of the KAI1 metastasis suppressor gene in epithelial ovarian carcinoma. Gynecol. Oncol. 2000; 78: 1015.
  • 29
    Higashiyama M, Kodama K, Yokouchi H et al. KAI1/CD82 expression in nonsmall cell lung carcinoma is a novel, favourable prognostic factor. Cancer 1998; 83: 46674.
  • 30
    Japanese Urological Association and the Japanese Society of Pathology. General Rule for Clinical and Pathological Studies on Bladder Cancer. Kanehara, Tokyo, 2001.
  • 31
    Sobin LH, Wittekind C. TNM Classification of Malignant Tumors. Wiley-Liss, New York, 1997.
  • 32
    Mostofi FK, Davis CJ, Sesterhenn IA. Histological typing of urinary bladder tumors. In: World Health Organization International Histological Classification of Tumor, 2nd edn. Springer, New York, 1999.
  • 33
    Pfister C, Moore L, Allard P et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin. Cancer Res. 1999; 5: 407984.
  • 34
    Uzawa K, Ono K, Suzuki H et al. High prevalence of decreased expression of KAI1 metastasis suppressor in human oral carcinogenesis. Clin. Cancer Res. 2000; 28: 82835.
  • 35
    Wright MD, Tomlinson MG. The ins and outs of the transmembrane 4 superfamily. Immunol. Today 1994; 15: 58894.
  • 36
    Geradts J, Maynard R, Birrer MJ et al. Frequent loss of KAI1 expression in squamous and lymphoid neoplasms: An immunohistochemical study of archival tissues. Am. J. Pathol. 1999; 154: 166571.
  • 37
    Fukudome K, Furuse M, Imai T et al. Identification of membrane antigen C33 recognized by monoclonal antibodies inhibitory to human T-cell leukemia virus type 1 (HTLV-1)-induced syncytium formation: Altered glycosylation o f C33 antigen in HTLV-1-positive T cells. J. Virol. 1992; 66: 1394401.
  • 38
    Miyazaki T, Kato H, Shitara Y et al. Mutation and expression of the metastasis suppressor gene KAI1 in esophageal squamous cell carcinoma. Cancer 2000; 89: 95562.
  • 39
    Shinohara T, Miki T, Nishimura N et al. Nuclear factor-kappaB-dependent expression of metastasis suppressor KAI1/CD82 gene in lung cancer cell lines expressing mutant p53. Cancer Res. 2001; 61: 6738.
  • 40
    Yu Y, Yang JL, Markovic B et al. Loss of KAI1 messenger RNA expression in both high-grade and invasive human bladder cancers. Clin. Cancer Res. 1997; 3: 10459.
  • 41
    Thykjaer T, Workman C, Kruhoffer M et al. Identification of gene expression patterns in superficial and invasive human bladder cancer. Cancer Res. 2001; 61: 24929.